Effect of PARP inhibitors on the ischemia-reperfusion-induced inactivation of respiratory complexes
| Treatment | Cytochrome oxidase | NADH:Cytochrome c Oxidoreductase |
|---|---|---|
| % of normoxic value | ||
| Normoxic | 100 ± 3.2 | 100 ± 2.9 |
| IR | 69.1 ± 2.3 | 68.3 ± 2.4 |
| IR +3-AB | 99.3 ± 2.83-150 | 93.6 ± 2.93-150 |
| IR+ 3-ABA | 65.7 ± 3.1 | 67.4 ± 2.1 |
| IR +nicotinamide | 97.5 ± 2.43-150 | 93.5 ± 3.13-150 |
| IR + BGP-15 | 97.8 ± 3.23-150 | 94.4 ± 3.23-150 |
| IR +4HQ | 95.2 ± 4.13-150 | 97.2 ± 3.83-150 |
Conditions for heart perfusion and the measurement of mitochondrial enzyme activities were detailed under Materials and Methods. Concentration of the applied chemicals were 3 mM for 3-aminobenzamide (3-AB), 3-aminobenzoic acid (3-ABA) and nicotinamide, 0.114 for mM BGP-15, and 0.1 for mM 4-hydroxyquinazoline (4-HQ). Values are given as mean ± S.E.M. for five experiments.
Difference from ischemia-reperfusion group
↵3-150 p < 0.01.